WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571319

CAS#: 1185887-21-1

Description: AB-PINACA is a synthetic cannabinoid drug that can induce hypothermia and bradycardia. It is an agonist for cannabinoid receptors.

Price and Availability




AB-PINACA is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 571319
CAS#: 1185887-21-1
Chemical Formula: C18H26N4O2
Exact Mass: 330.2056
Molecular Weight: 330.43
Elemental Analysis: C, 65.43; H, 7.93; N, 16.96; O, 9.68

Synonym: AB-PINACA

IUPAC/Chemical Name: N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide


InChi Code: InChI=1S/C18H26N4O2/c1-4-5-8-11-22-14-10-7-6-9-13(14)16(21-22)18(24)20-15(12(2)3)17(19)23/h6-7,9-10,12,15H,4-5,8,11H2,1-3H3,(H2,19,23)(H,20,24)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59. doi: 10.1021/acschemneuro.5b00112. Epub 2015 Jul 17. PubMed PMID: 26134475.

2: Hsin-Hung Chen M, Dip A, Ahmed M, Tan ML, Walterscheid JP, Sun H, Teng BB, Mozayani A. Detection and Characterization of the Effect of AB-FUBINACA and Its Metabolites in a Rat Model. J Cell Biochem. 2016 Apr;117(4):1033-43. doi: 10.1002/jcb.25421. Epub 2015 Nov 24. PubMed PMID: 26517302; PubMed Central PMCID: PMC5063098.

3: Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K; INDICES Consortium. Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. 2015 Jul;7(7):565-76. doi: 10.1002/dta.1731. Epub 2014 Oct 24. PubMed PMID: 25346527.

4: Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo'oka T. UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome. Biomed Chromatogr. doi: 10.1002/bmc.3155. PubMed PMID: 24861751.

5: Longworth M, Banister SD, Mack JBC, Glass M, Connor M, Kassiou M. The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicol. 2016;34:286-303. doi: 10.1007/s11419-016-0316-y. Epub 2016 Apr 27. PubMed PMID: 27547266; PubMed Central PMCID: PMC4971050.

6: Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule. Fed Regist. 2016 Sep 6;81(172):61130-3. PubMed PMID: 27632803.

7: Murakami T, Iwamuro Y, Ishimaru R, Chinaka S, Sugimura N, Takayama N. Differentiation of AB-FUBINACA positional isomers by the abundance of product ions using electron ionization-triple quadrupole mass spectrometry. J Mass Spectrom. 2016 Nov;51(11):1016-1022. doi: 10.1002/jms.3814. PubMed PMID: 27441731.

8: Drug Enforcement Administration, Department of Justice. Schedules of Controlled Substances: Extension of Temporary Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA in Schedule I of the Controlled Substances Act. Final order. Fed Regist. 2016 Feb 5;81(24):6175-7. PubMed PMID: 26859904.

9: Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M, McGregor IS. Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. J Psychopharmacol. 2017 Jun;31(6):757-769. doi: 10.1177/0269881116684336. Epub 2017 Jan 16. PubMed PMID: 28093016.

10: Vikingsson S, Gréen H, Brinkhagen L, Mukhtar S, Josefsson M. Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Test Anal. 2016 Sep;8(9):950-6. doi: 10.1002/dta.1896. Epub 2015 Nov 11. PubMed PMID: 26560240.

11: Klavž J, Gorenjak M, Marinšek M. Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC. Forensic Sci Int. 2016 Aug;265:121-4. doi: 10.1016/j.forsciint.2016.01.018. Epub 2016 Jan 28. PubMed PMID: 26890319.

12: Canazza I, Ossato A, Vincenzi F, Gregori A, Di Rosa F, Nigro F, Rimessi A, Pinton P, Varani K, Borea PA, Marti M. Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA, and STS-135 in mice. In vitro and in vivo studies. Hum Psychopharmacol. 2017 May;32(3). doi: 10.1002/hup.2601. Epub 2017 Jun 9. PubMed PMID: 28597570.

13: Lam RPK, Tang MHY, Leung SC, Chong YK, Tsui MSH, Mak TWL. Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Clin Toxicol (Phila). 2017 Aug;55(7):662-667. doi: 10.1080/15563650.2017.1307385. Epub 2017 Apr 10. PubMed PMID: 28393558.

14: Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav Pharmacol. 2015 Aug;26(5):460-8. doi: 10.1097/FBP.0000000000000150. PubMed PMID: 26061356; PubMed Central PMCID: PMC4497846.

15: Hess C, Stockhausen S, Kernbach-Wighton G, Madea B. Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Sci Int. 2015 Dec;257:e6-11. doi: 10.1016/j.forsciint.2015.08.012. Epub 2015 Aug 29. PubMed PMID: 26363623.

16: Hess C, Krueger L, Unger M, Madea B. Freeze-thaw stability and long-term stability of 84 synthetic cannabinoids in serum. Drug Test Anal. 2016 Nov 8. doi: 10.1002/dta.2133. [Epub ahead of print] PubMed PMID: 27863089.

17: Vaiano F, Busardò FP, Palumbo D, Kyriakou C, Fioravanti A, Catalani V, Mari F, Bertol E. A novel screening method for 64 new psychoactive substances and 5 amphetamines in blood by LC-MS/MS and application to real cases. J Pharm Biomed Anal. 2016 Sep 10;129:441-449. doi: 10.1016/j.jpba.2016.07.009. Epub 2016 Jul 7. PubMed PMID: 27490334.

18: Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order. Fed Regist. 2014 Feb 10;79(27):7577-82. PubMed PMID: 24605391.

19: Maeda H, Kikura-Hanajiri R, Kawamura M, Nagashima E, Yoshida KI. AB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema. Clin Toxicol (Phila). 2017 Jul 14:1-3. doi: 10.1080/15563650.2017.1340648. [Epub ahead of print] PubMed PMID: 28707493.

20: Behonick G, Shanks KG, Firchau DJ, Mathur G, Lynch CF, Nashelsky M, Jaskierny DJ, Meroueh C. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 2014 Oct;38(8):559-62. doi: 10.1093/jat/bku048. Epub 2014 May 29. PubMed PMID: 24876364; PubMed Central PMCID: PMC4334789.